pharma · Polycythemia Vera (PV) · Primary Myelofibrosis
PharmaEssentia
PharmaEssentia is a pharma organization headquartered in CN. Primary therapeutic focus areas include Polycythemia Vera (PV), Primary Myelofibrosis. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and 0 pat
Burlington, USA HQ
2003 Founded
356 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- Burlington, USA
- Founded
- 2003
- Employees
- 356
- Programs
- 2
- Drugs
- 3
- Patents
- 0
P1101
Phase 3 · small molecule · Polycythemia Vera (PV)
P1101 for Polycythemia Vera (PV) is a Phase 3 program (small_molecule) at PharmaEssentia with 1 ClinicalTrials.gov record(s).
Internal code A23-301
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- PharmaEssentia
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Polycythemia Vera (PV)
- Status
- completed
- Trials
- 1